Spun out of research variously undertaken at University of Manitoba, University of California San Diego, and University of Toronto, Winsantor is a clinical-stage biotechnology company organized around discovery and development of treatments for peripheral neuropathies The company is developing a proprietary drug therapy for preventing - and reversing - nerve damage. Winsanter personel have identified a class of compounds and a novel pathway resulting in neuroprotecton and neuroregeneration of the degenerating neurons that cause neuropathy. The firm's lead compound, WST01, is previously approved for a sepearte use and has an established safety record. The compound prevents mitochondrial dysfunction, nerve fiber depletion and sensory loss in several distinct animal models of peripheral neuropathy.
